Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002

Pediatric Infectious Disease Journal

Volumn 23, Issue 1, 2004, Pages 27-31

  Henckel, Ewa ^b   Luthander, Joachim ^a   Berggren, Eva ^a,c   Kapadia, Hanna ^a   Navér, Lars ^b   Norman, Mikael ^c   Bennet, Rutger ^c   Eriksson, Margareta ^c  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b Children's Hospital   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Infants; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; PALIVIZUMAB; STEROID;

ARTICLE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NEWBORN; NONHUMAN; OXYGEN THERAPY; PREMATURITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY; SWEDEN; TREATMENT OUTCOME; URBAN POPULATION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; PRIMARY PREVENTION; PROBABILITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SWEDEN; TREATMENT OUTCOME; URBAN POPULATION;

EID: 0842282783     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000105106.93562.d3     Document Type: Article

References (19)

1. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
2. Atkins JT, Karimi P, Morris BH, McDavid G, Shim S. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J 2000;19:138-43.
3. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20: 874-9.
4. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-8.
5. Lacaze-Masmonteil T, Roze JC, Fauroux B. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis. Pediatr Pulmonol 2002;34:181-8.
6. Oh PI, Lanctjt KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002;21:512-18.
7. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000;19:1068-71.
8. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-41.
9. Swedish Consensus Group. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis 2001;33: 323-8.
10. Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91:593-8.
11. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus: International RSV Study Group. Eur J Pediatr 1998;157:215-20.
12. Redding GJ, Braun S, Mayock D. Impact of respiratory syncytial virus immune globulin in 1996-1997: a local controlled comparison. Arch Pediatr Adolesc Med 1999;153: 503-7.
13. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT. Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr Infect Dis J 1999;18:850-3.
14. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61.
15. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
16. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
17. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002;34: 262-6.
18. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
19. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 1998;102:1211-16.